Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment

International Journal of Technology Assessment in Health Care

Volumn 27, Issue 3, 2011, Pages 193-200

  Kobelt, Gisela ^a,b   Lekander, Ingrid ^c,d   Lang, Andrea ^d   Raffeiner, Bernd ^e   Botsios, Costantino ^e   Geborek, Pierre ^a,f  

^a LUND UNIVERSITY   (Sweden)

^b European Health Economics   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

^d I3 Innovus ^*  (Sweden)

^e UNIVERSITY OF PADOVA   (Italy)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost effectiveness; Dose reduction; Etanercept; Rheumatoid arthritis; Sweden

Indexed keywords

BIOLOGIC TREATMENT; CLINICAL PRACTICES; CLINICAL TRIAL; DOSE ADJUSTMENTS; DOSE REDUCTION; ETANERCEPT; FUNCTIONAL CAPACITY; INCREMENTAL COST; MICROSIMULATION; OBSERVATIONAL STUDY; POLICY IMPLICATIONS; RHEUMATOID ARTHRITIS; SWEDEN; TIME HORIZONS;

COMPUTER SIMULATION; COST EFFECTIVENESS; COSTS; EXPERIMENTS; HEALTH; PUBLIC POLICY; SENSITIVITY ANALYSIS;

PATIENT TREATMENT;

ETANERCEPT; METHOTREXATE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG DOSE REDUCTION; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SWEDEN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SWEDEN;

EID: 80155157726     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462311000195     Document Type: Article

References (25)

1. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005;64:995-1002.
2. Botsios C, Furlan A, Ostuni P, et al. Effects of low-dose etanercept in maintaining DAS-remission previously achieved with standrad dose in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;66:54.
3. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
4. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine. 2009;76:350-355.
5. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: Report of atask force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.
6. Emery P, Breedveld F, Heijde Dvd, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study. Arthritis Rheum. 2010;62:674-682.
7. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
8. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48:54-58.
9. Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology (Oxford). 2000;39:1159-1161.
10. Jacobsson LT, Lindroth Y, Marsal L, et al. Rheumatoid arthritis: What does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol. 2007;36:179-183.
11. Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10:357-359.
12. Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF inhibitor in RA: Results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:507-513.
13. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis. 2004;63:4-10.
14. Kobelt G, Jönsson L, Young A, Eberhardt K. The costeffectiveness of infliximab (Remicade (R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology. 2003;42:326-335.
15. Kobelt G, Kasteng F. Access to innovative treatments in rheumatpid arthritis in Europe. Lund, Sweden: Lund University; 2009. www.comparatorreports. se.
16. Kobelt G, Lindgren P, Geborek P. Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: Amodel based on registry data. Scand J Rheumatol. 2009;38:409-418.
17. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64:1174-1179.
18. Lagana B, Picchianti Diamanti A, Ferlito C, et al. Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption. Int J Immunopathol Pharmacol. 2009;22:447-454.
19. Lekander I, Borgstrom F, Svarvar P, et al. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care. 2010;26:54-61.
20. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis. 1999;58:11-14.
21. Nishimoto N. Drug-free remission after cessation of actemra monotherapy (DREAM study). Ann Rheum Dis. 2010;69:98.
22. Scott D, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology. 2000;39:122-132.
23. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.
24. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975.
25. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914-921.